Moreover, LOLA is not limited to treating only overt hepatic encephalopathy; it has also been investigated for its preventive role in patients at risk of developing this condition. By proactively lowering ammonia levels, LOLA may help mitigate the incidence of encephalopathy in patients with advanced liver disease.
Pentoxifylline, a xanthine derivative, is primarily known for its ability to improve blood flow. It has garnered attention for its therapeutic applications in various medical conditions, particularly those associated with vascular insufficiencies. The drug’s notable formulation, Pentoxifylline 400, is characterized by its sustained-release properties, allowing for a more consistent therapeutic effect with fewer side effects.